A nonpeptide vasopressin V2 receptor antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lixivaptan

Item No. 21511

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl-benzamide
CAS Number
168079-32-1
Synonyms
  • VPA-985
  • WAY-VPA-985
Molecular Formula
C27H21ClFN3O2
Formula Weight
473.9
Purity
≥97%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS(pH 7.2) (1:2): 0.33 mg/mlEthanol: 10 mg/ml
λmax
268 nm
SMILES
CC1=CC=C(F)C=C1C(NC2=CC(Cl)=C(C(N3C(C=CC=C4)=C4CN5C(C3)=CC=C5)=O)C=C2)=O
InChi Code
InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
InChi Key
PPHTXRNHTVLQED-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $103

    Add

    10 mg

    $186

    Add
    Product Description

    Lixivaptan is a nonpeptide antagonist of vasopressin V2 receptors (Ki = 2.3 nM).1 It is 100-fold selective for V2 over V1a.2 Formulations containing lixivaptan decrease urinary excretion of aquaporin-2 in patients with chronic heart failure and increase serum sodium levels in patients with hyponatremia due to congestive heart failure.3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Matthews, J.M., Hoekstra, W.J., Dyatkin, A.B., et al. Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates. Bioorg. Med. Chem. Lett. 14(11), 2747-2752 (2004).

    2. Izumi, Y., Miura, K., and Iwao, H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. J. Pharmacol. Sci. 124(1), 1-6 (2014).

    3. Bowman, B.T., and Rosner, M.H. Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia. Core Evid. 8, 47-56 (2013).

    4. Martin, P.-Y., Abraham, W.T., Lieming, X., et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J. Am. Soc. Nephrol. 10(10), 2165-2170 (1999).